
Beyond Air, Inc.
- Jurisdiction
United States - LEI
549300GFTTTXX5728360 - ISIN
US08862L1035 (XAIR )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. Read full profile
Fundamentals
- Net revenue
€4.08M - Gross margin
-24.6% - EBIT
-€32.90M - EBIT margin
-806.7% - Net income
-€35.92M - Net margin
-880.7%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Lisi Steven A. | CEO and Chairman of the Board |
|
|
|
|
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
George Soros |
|
|
|
Sell |
Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: June 24, 2024 (Q4 2024)